Additional Non-Small Cell Lung Cancer Resources

Access an extensive list of additional non-small cell lung cancer (NSCLC) resources covering topics including biomarker testing, preanalytic indicators, immunohistochemistry, next generation sequencing, liquid biopsy, targeted therapies, quality, reporting, and billing/reimbursement.

Biomarker Testing

Molecular Diagnostics in NSCLC (5/2020)

Biomarker Testing for Patients with Advanced NSCLC: Real-World Issues and Tough Choices (ASCO Educational Book, 5/2019)

Current and Future Trends in NSCLC Biomarker Testing: The American Experience (9/2020)

Biomarkers for Lung Cancer Screening and Detection (12/2020)

Do More with Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience (3/2018)

Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine (7/2019)

Operational Pathways for Biomarker Testing in NSCLC Environmental Scan (2021)

Biomarker Testing and Time to Treatment Decision in Patients with Advanced NSCLC (7/2015)

Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing (6/2021)

Genomic Testing and Targeted Therapies May Be Underused in Community Practice (6/2019)

Abstract: Genomic Testing and Treatment Landscape in Patients with Advanced NSCLC Using Real-World Data from Community Oncology Practices (5/2019)

Biomarkers in Lung Cancer (first page preview only, 3/2020)

Preanalytic Indicators

A Preanalytics Push in Accreditation Checklists (9/2021)

Immunohistochemistry

Immunohistochemistry of Pulmonary Biomarkers: A Perspective from Members of the Pulmonary Pathology Society (7/2017)

Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in NSCLC (12/2020)

Diagnostic and Predictive Immunohistochemistry for NSCLC (abstract only, 11/2018)

IHC vs. FISH vs. NGS to Detect ALK Gene Rearrangement in NSCLC: All Questions Answered? (abstract only, 3/2021)

Next Generation Sequencing (NGS)

Preanalytic Variables and Tissue Stewardship for Reliable NGS Clinical Analysis (6/2019)

Concurrent Fine Needle Aspirations and Core Needle Biopsies: A Comparative Study of Substrates for NGS in Solid Organ Malignancies (1/2017)

Cost Effectiveness of Multigene Panel Sequencing for Patients with Advanced NSCLC (6/2019)

Markers, Methods Remake the NSCLC Map (2/2021)

Liquid Biopsy

Liquid Biopsy for Advanced NSCLC: A Statement Paper from the IASLC (6/2018)

Liquid Biopsy is a Valuable Tool in the Diagnosis and Management of Lung Cancer (11/2020)

Traditional Diagnostics vs. Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy (8/2020)

Targeted Therapies

Immunotherapy for Advanced NSCLC: A Decade of Progress (ASCO Educational Book, 5/2021)

NSCLC from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies (6/2020)

Advances in Treatment of Locally Advanced or Metastatic NSCLC: Targeted Therapy (6/2020)

The BATTLE Trial: Personalizing Therapy for Lung Cancer (10/2014)

ALK Inhibitors for NSCLC: A Systematic Review and Network Meta-Analysis (2/2020)

ALK Inhibitors in the Treatment of ALK-Positive NSCLC (1/2019)

Early-Stage NSCLC Treatment

Osimertinib in Resected EGFR-Mutated NSCLC (10/2020)

Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB–IIIA NSCLC (IMpower010) (Abstract only, 10/2021)

Quality

Fostering Quality (7/2019)

Harmonized Outcome Measures for Use in NSCLC Patient Registries and Clinical Practice (8/2021)

AHRQ Research White Paper: Standardized Library of Lung Cancer Outcome Measures (8/2021)

ACCC Poster: Defining High Quality NSCLC Care at US Cancer Centers (10/2020)

ACCC Poster: Improving NSCLC Care Delivery: Findings for Oncology Nurses and Patient Navigation from a National Quality Survey (11/2020)

ACCC Process Improvement Case Study: Goshen Center for Cancer Care (2017)

ACCC Process Improvement Case Study: Sarah Cannon Cancer Institute at Johnston-Willis Hospital (2017)

ACCC Process Improvement Case Study: Southside Regional Medical Center (2017)

Sample Tools from ASCP’s CQI Certificate Program:

Reporting

ACCC White Paper: Considerations for Pathology Reporting (2020)

ACCC White Paper: Patient-Centered Care: Reporting and Communicating Pathology and Ancillary Test Results (2020)

Billing/Reimbursement

AMP Report: Molecular Pathology Economics 101: An Overview of Molecular Diagnostics Coding, Coverage, and Reimbursement (8/2020)

CMS Billing and Coding: Molecular Pathology Procedures (updated on 2/2021)

CMS National Coverage Decision for NGS (90.2) (effective date 1/2020)

Patient Resources

Lungevity Patient Education

Acknowledgements and Commercial Support

This resource page was initially developed in collaboration with the Association of Community Cancer Centers (funded by an independent educational grant from Pfizer, Inc.), and further expanded upon through a commercial sponsorship from Genentech.

Connect today with your local Genentech biomarker testing specialist at: biomarkertesting.com/contact. To learn more about Genentech, please visit gene.com

ASCP does not share identifying information from the action plans with its sponsors.

Copyright ©2021 by American Society for Clinical Pathology. All Rights Reserved.

Callback Request

Name		*
Country Code		*
Phone Number		*
Scheduled Date		*
Scheduled Time		*
Customer Id